Should you buy Innospec stock now?
Yes, the technical signal for Innospec is currently Strong Buy. Innospec trades at $98.64 as of Oct 24, 2026. The technical analysis shows the following: MACD is positive (bullish trend) at 1.082 with rising momentum (signal: 1.030); RSI is at 59.1 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $101.00 points to 2.4% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Innospec stock?
The average analyst price target for Innospec is $101.00. The current price is $98.64, which gives an upside of 2.4%. Based on this, the stock is considered fairly valued. The fair value range (±10% of the price target) is between $90.90 and $111.10.
Is Innospec a dividend stock?
Yes, Innospec is a dividend stock with a dividend yield of 1.81%. The latest dividend was $0.92 per share. The latest ex-dividend date (traded without the dividend) was May 19, 2026. The payout ratio is 36.2%, which is considered sustainable.
When does Innospec pay a dividend in 2026?
The next dividend date for Innospec has not been set yet. The latest ex-dividend date (last trading day with dividend rights) was May 19, 2026. The latest dividend was $0.92 per share with an ex-dividend date of May 19, 2026. The dividend yield is 1.81%. The payout ratio of 36.2% points to a sustainable dividend with room to grow.
What is the risk of Innospec stock?
Innospec is rated as a stock in the risk category Conservative. the annual standard deviation is 23.3%, which classifies the stock as Conservative.
Is Innospec overvalued?
Innospec is considered fairly valued – the price is close to the analyst price target. Innospec has the following valuation ratios: a P/E ratio of 20.1 (moderately to highly valued), a P/S ratio of 1.3, a P/B ratio of 1.8. The stock trades close to the analyst price target and is considered fairly valued.
Is Innospec overbought?
No, Innospec is not overbought. RSI is at 59.1 (neutral zone). The technical indicators show: RSI is at 59.1 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 1.3% above the 20-day average (short-term uptrend). In addition, MACD is positive with rising momentum (bullish).
When is the next Innospec earnings report?
Innospec reports its next earnings on November 3, 2026. The stock currently trades at $98.64. With a P/E ratio of 20.1, the market will be watching closely whether earnings meet expectations.
Is Innospec shorted?
Yes, Innospec is shorted with 2.8% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. The figure comes from our data provider EODHD, is reported about twice a month, and we check it every trading day.
Are insiders buying Innospec stock?
No, insiders are not buying Innospec shares – they are net sellers. Across the last 20 reported transactions, the split is 1 purchases and 19 sales, with a net 2,085,257 $ sold. Active sellers include Jones David B., Poccia Claudia, PADFIELD Larry and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Innospec a good stock?
Based on our total score, Innospec is rated as a good stock with a total score of 69 out of 100. The stock scores above average on value, quality and momentum. The score is made up of Value: 71/100, Quality: 46/100, Momentum: 90/100. In addition: a dividend of 1.81%. Whether now is the time to buy is a separate question: the technical signal is Strong Buy. Whether Innospec is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Innospec stock?
The outlook for Innospec based on current data: the average analyst price target is $101.00 (+2.4%); the stock is in an uptrend (above SMA50 and SMA200); the next earnings report is due on Nov 3, 2026, which can move the price; the P/E ratio is 20.1 (moderate). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Innospec stock moving?
Innospec is stable right now. The technical indicators show: the price is close to the 20-day average; MACD is positive with rising momentum (bullish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis and insider section above.
How high can Innospec go?
The average analyst price target for Innospec is $101.00, which corresponds to a potential gain of 2.4% from the current price of $98.64. The stock has traded between $64.75 and $100.48 over the last 52 weeks. The price is close to the 52-week high. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Innospec fall?
The stock has traded as low as $64.75 over the last 52 weeks — that is 34.4% below the current price of $98.64. The biggest decline (drawdown) in the same period was 35.6% from high to low. Within a year, the price typically swings about ±23.3% (standard deviation — a measure of price swings). A difficult year could therefore mean a further decline of that size. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Innospec do?
Innospec Inc. develops, manufactures, blends, markets, and supplies specialty chemicals in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company operates through three segments: Performance Chemicals, Fuel Specialties, and Oilfield Services. It offer... The company belongs to the Basic Materials sector, more specifically the Specialty Chemicals industry, is headquartered in United States, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Innospec as an investment.
Did Innospec raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Innospec. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history above.
Is Innospec making money or losing money?
Yes, Innospec is making money, not losing it. The company has a profit margin (the share of revenue left over as profit) of 6.6% — which is moderate. The operating margin (profit before interest and taxes) is 8.1%. At a P/E ratio of 20.1, you currently pay 20.1 dollars for every dollar of the company's annual earnings. A consistently profitable company is usually more resilient than growth stocks that are not yet making money.
Can Innospec go bankrupt?
The bankruptcy risk of Innospec is rated as low. Altman Z2 (a model for assessing financial distress) is 7.70 — that places the company in the healthy zone. The company has a healthy balance sheet with limited debt relative to earnings and assets. The Piotroski score (financial health 0-9, higher is better) is 6 — which is average. Debt relative to equity is 43% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Innospec have a lot of debt?
No, Innospec has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 43%. For the basic materials sector, anything below 70% counts as low debt. Commodity companies finance mines and plants with moderate debt — 70-150% is typical. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.